Compare BAND & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | ACHV |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.9M | 618.0M |
| IPO Year | 2017 | 2018 |
| Metric | BAND | ACHV |
|---|---|---|
| Price | $78.53 | $6.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $24.50 | $14.67 |
| AVG Volume (30 Days) | 1.6M | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.50 | $2.38 |
| 52 Week High | $75.98 | $7.11 |
| Indicator | BAND | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 72.38 | 62.10 |
| Support Level | $14.27 | $4.09 |
| Resistance Level | N/A | $7.11 |
| Average True Range (ATR) | 5.05 | 0.47 |
| MACD | 1.67 | 0.04 |
| Stochastic Oscillator | 99.48 | 67.47 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.